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Drug interactionThe DDIExtraction Shared Task 2013 is the second edition of the DDIExtraction Shared Task series, a
community-wide effort to promote the implementation and comparative assessment of natural language
processing (NLP) techniques in the ﬁeld of the pharmacovigilance domain, in particular, to address the
extraction of drug–drug interactions (DDI) from biomedical texts. This edition has been the ﬁrst attempt
to compare the performance of Information Extraction (IE) techniques speciﬁc for each of the basic steps
of the DDI extraction pipeline. To attain this aim, two main tasks were proposed: the recognition and
classiﬁcation of pharmacological substances and the detection and classiﬁcation of drug–drug interac-
tions. DDIExtraction 2013 was held from January to June 2013 and attracted wide attention with a total
of 14 teams (6 of the teams participated in the drug name recognition task, while 8 participated in the
DDI extraction task) from 7 different countries. For the task of the recognition and classiﬁcation of phar-
macological names, the best system achieved an F1 of 71.5%, while, for the detection and classiﬁcation of
DDIs, the best result was an F1 of 65.1%. The results show advances in the state of the art and demonstrate
that signiﬁcant challenges remain to be resolved. This paper focuses on the second task (extraction of
DDIs) and examines its main challenges, which have yet to be resolved.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Pharmacovigilance is formally deﬁned by the WHO as ‘‘the
science and activities related to the detection, assessment, under-
standing and prevention of adverse effects or any other drug-
related problems’’ [1]. One of the major aims of pharmacovigilance
is the early detection of adverse drug reactions (ADRs), which are
unintended and harmful reactions to drugs. Several studies point
out that the number of ADRs has increased signiﬁcantly in recent
years [2] and are responsible for about 5% of all hospital admis-
sions [3,4]. More seriously, ADRs cause more than 300,000 deaths
per year in the USA and Europe [5,6]. As a result, ADRs are a direct
cause of the increase in health care costs [2]. Thus, the pharmaco-
vigilance process is considered vital by pharmaceutical companies
and drug agencies due to the high and growing incidence of drug
safety incidents as well as their high associated costs.
Healthcare professionals are responsible for recognizing and
reporting side effects by spontaneous post-marketing reporting
systems. However several published drug safety issues have shown
that the adverse effects of drugs may be detected too late, when
millions of patients have already been exposed to them [7]. Thisfact poses a serious problem for patient safety giving rise to a
growing interest in improving the early detection of ADRs. Drug–
Drug Interactions (DDIs), which can be deﬁned as alterations in
the effects of a drug due to the recent use or simultaneously one
or more other drugs, are an important subset of ADRs. Although
there are different databases supporting healthcare professionals
in the detection of DDIs (such as DrugBank [8]), the quality of these
databases is very uneven and the consistency of their content is
limited, so it is very difﬁcult to assign a real clinical signiﬁcance
to each interaction [9,10]. On the other hand, these databases do
not scale well to the large and growing number of pharmacovigi-
lance literature in recent years [10]. In addition, a large amount
of the most current and valuable information is unstructured, writ-
ten in natural language and hidden in published articles, scientiﬁc
journals, books and technical reports [11]. Thus, the large number
of databases with information on DDIs and the deluge of published
research have overwhelmedmost healthcare professionals because
it is not possible to remain up to date on everything published
about DDIs.
Therefore, there is an increasing interest in facilitating auto-
mated access to information relevant on DDIs described in biomed-
ical texts. Information Extraction (IE) techniques applied to
pharmacovigilance literature can be of great beneﬁt in the pharma-
ceutical industry allowing the identiﬁcation and extraction of rele-
vant information and providing an interesting way of reducing the
Table 1
Numbers of the annotated entities in the DDI corpus.
DDI-DrugBank DDI-MedLine Total
DRUG 9901 (63%) 1745 (63%) 11,646 (63%)
BRAND 1824 (12%) 42 (1.5%) 1866 (10%)
GROUP 3901 (25%) 324 (12%) 4225 (23%)
DRUG_N 130 (1%) 635 (23%) 765 (4%)
TOTAL 15,756 2746 18,502
Table 2
Numbers of the annotated relationships in the DDI corpus.
DDI-DrugBank DDI-MedLine Total
EFFECT 1855 (39.4%) 214 (65.4%) 2069 (41.1%)
MECHANISM 1539 (32.7%) 86 (26.3%) 1625 (32.3%)
ADVICE 1035 (22%) 15 (4.6%) 1050 (20.9%)
INT 272 (5.8%) 12 (3.7%) 284 (5.6%)
TOTAL 4701 327 5028
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ing the literature.
With the support of collaborative events such as BioCreative
[12–15], BioNLP [16–18], i2b2 [19,20], ShARe/CLEF eHealth [21]
and SemEval-2014 Task 7 Analysis of Clinical Texts1 shared tasks,
there has been signiﬁcant progress in IE techniques in the biological
domain. However IE technology applied to pharmacovigilance still
remains quite unexplored compared to biology.
The extraction of DDIs from biomedical texts has gained popu-
larity and has seen signiﬁcant advances recently with the organiza-
tion of the DDIExtraction Shared Tasks in 2011 [22] and 2013 [23].
The main goal of these community challenges is to provide a com-
mon framework for the evaluation of information extraction tech-
niques applied to the extraction of DDIs from biomedical texts.
While the ﬁrst event in 2011 only focused on the identiﬁcation
of all possible pairs of interacting drugs, the 2013 edition also
included, in addition to DDI detection, the classiﬁcation of each
DDI. Furthermore, a supporting task, the recognition and classiﬁca-
tion of pharmacological substances, was proposed in 2013.
In the latest edition of DDIExtraction, a total of 14 teams sub-
mitted runs for at least one of the proposed subtasks (6 of the
teams participated in the drug name recognition task, while 8 par-
ticipated in the DDI extraction task). In the drug name recognition
subtask, the top scoring team reached an F-score of 71.5%. In the
relation extraction task, the best system achieved an F1 of 65.1%.
This paper focuses on the second task (extraction of DDIs). The
aim of this paper is twofold: to provide a detailed description
and discussion on the 8 participating systems in the second task,
the extraction of DDIs, and to discuss the remaining challenges
revealed by the error analysis on these systems.
This paper proceeds as follows: Section 2 describes the corpus
used in the shared task; in Section 3 we give a detailed discussion
of the participating systems; Section 4 presents the results
obtained by the participating systems; Section 5 describes the
major sources of errors in these systems; Section 6 presents a
study as to whether the results are signiﬁcant statistically; in Sec-
tion 7 we propose an ensemble system of combining the top three
methods using majority and union voting strategies; and ﬁnally,
we close with a discussion in Section 8 of possible future steps of
the DDIExtraction Shared Task.2. The DDI corpus
The major contribution of DDIExtraction has been to provide a
benchmark corpus, the DDI corpus. The DDI corpus is a valuable
gold-standard for those research groups interested in the recogni-
tion of pharmacological substances or those speciﬁcally working in
the ﬁeld of DDI relation extraction. It consists of 792 texts selected
from the DrugBank database (DDI-DrugBank dataset) and other
233 Medline abstracts (DDI-MedLine dataset) on the subject of
DDIs. The corpus was manually annotated with a total of 18,502
pharmacological substances and 5028 DDIs, including both phar-
macokinetic (PK) as well as pharmacodynamic (PD) interactions.1 http://alt.qcri.org/semeval2014/task7/. 2 http://corpora.informatik.hu-berlin.de/.Four entity types were proposed to annotate pharmacological sub-
stances: drug, brand, group and drug_n. The drug type is used to
annotate those human medicines known by a generic name,
whereas those drugs described by a trade or brand name are anno-
tated as brand entities. The use of either generic or brand names
depends on the drug information source. Thus, while generic
names are used in medical and pharmacological textbooks as well
as scientiﬁc medical journals, brand names are used in drug prod-
uct labels. The group type was used to annotate groups of drugs.
This type was included because the descriptions of DDIs involving
groups of drugs are very common in texts. The last entity type,
drug_n, refers to those active substances not approved for human
use, such as toxins or pesticides. This type was included because
interactions between drugs and substances not approved for
human use are frequently reported in Medline documents.
DDIs were annotated at the sentence level and, thus, interac-
tions spanning over several sentences were not annotated. Four
different types of DDI relationships are proposed: mechanism (this
type is used to annotate DDIs that are described by their pharma-
cokinetic mechanism), effect (this type is used to annotate DDIs
describing an effect or a pharmacodynamic mechanism), advice
(this type is used when a recommendation or advice regarding a
drug interaction is given) and int (this type is used when a DDI
appears in the text without providing any additional information).
Tables 1 and 2 show the numbers of the annotated entities and
relationships in each corpus, respectively.
Fig. 1 shows some examples of annotated texts in the DDI
corpus. This ﬁgure has been taken from the WBI corpora repos-
itory.2 The DDI corpus was adapted to the Stav format by the WBI
team in order to be visualized using Stav on-line visualization tool
[24]. The ﬁrst example (A), taken from the MedLineDDI dataset,
describes a DDI of mechanism type between a drug (named using
a synonym different from its most common generic name,
fomepizole) that inhibits the metabolism of a substance not-
approved to be used in humans (1,3-diﬂuoro-2-propranol). The
second example (B) is also a sentence taken from MedLine and
describes the consequence of a DDI (effect type) between estradiol
(a generic drug) and endotoxin (a drug-n) in an experiment
performed in animals. The last example (C) is a paragraph from
the DDI-DrugBank dataset. Its ﬁrst sentence describes the conse-
quence of the interaction (effect type) of a drug, denominated
by its brand name (Inapsine), when is co-administered with ﬁve
different groups of drugs. The third sentence in C shows a recom-
mendation to avoid these DDIs (advice type).
Inter-annotator agreement (IAA) was measured in order to
assess the consistency and quality of the corpus as well as the com-
plexity of the annotation task. Tables 3 and 4 present the results for
the agreement per type of entity and per type of relationship,
respectively. Results were calculated in terms of the standard
Kappa statistic [25]. The overall IAA results suggest that the DDI
corpus has enough quality to be used for training and testing
NLP techniques applied to the ﬁeld of pharmacovigilance. A
detailed description of the DDI corpus can be found in [26].
Fig. 1. Example sentences in the DDI corpus.
Table 3
IAA results of the annotated entities in the DDI corpus.
DDI-DrugBank DDI-MedLine
KDRUG 0.9534 0.8467
KBRAND 0.9569 0.8853
KGROUP 0.9563 0.8299
KDRUG n 0.4422 0.8122
K 0.9104 0.7962
Table 4
IAA results of the annotated relationships in the DDI corpus.
DDI-DrugBank DDI-MedLine
KEFFECT 0.7525 0.5548
KMECHANISM 0.4214 0.5577
KADVICE 0.9428 0.5587
KINT 0.9558 0.7252
K 0.8385 0.6213
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This section reviews the 8 systems participating in the task of
extracting DDIs and presents their results. For the evaluation of
this task, the participants were given the test data with gold anno-
tation only for pharmacological substances. The evaluation was
then carried out by comparing the annotation predicted by each
participant to the gold annotation. To simplify the task, the detec-
tion of DDIs was conducted at the sentence-level. The evaluation
results are reported using the standard recall/precision/f-measure
metrics, under different criteria: partial (only detection of DDIs)
and exact (detection and classiﬁcation of DDIs).3.1. Fondazione Bruno Kessler team (FBK-irst)
The system consisted of two separate steps: ﬁrst the DDIs were
detected and second, the extracted DDIs were classiﬁed according
to the proposed types (mechanism, effect, advice and int) in the
guidelines task. In the DDI detection phase, ﬁltering techniques
based on the scope of negation cues and the semantic roles of
the entities involved were proposed to rule out possible negative
instances from the test dataset. In particular, a binary SVM classi-
ﬁer was trained using contextual and shallow linguistic features to
ﬁnd less informative sentences. A sentence is considered less infor-
mative when all its entities as well as its relation clues fall under
the scope of a negation cue (no, n’t, not). Less informative sen-
tences were not considered in the relation extraction phase. Also,
less informative negative instances were ruled out according to
the following exclusion criteria: (1) if two mentions in a sentence
refer to the same entity, this pair is not considered as a candidate
DDI, (2) for any expression of the form ‘‘Drug1 (Drug2)’’, the pair
was ruled out because both entities refer to the same entity (Drug2
is usually the abbreviation of Drug1), and (3) a candidate pair was
ruled out when its two mentions had anti-positive governors with
respect to the type of the relation. Anti-positive governors are
words that tend to prevent mentions, which are directly dependent
on those words, from participating in a certain relation of interest
with any other mention in the same sentence [27]. We refer the
reader to [28] for detailed description of anti-positive governors.Once these negative instances were discarded from the test
dataset, a hybrid kernel (combining a feature-based kernel, the
shallow linguistic kernel (SL) [29] and the Path-enclosed Tree
(PET) kernel [30]) was used to train a RE classiﬁer. For the classiﬁ-
cation of the extracted DDIs, four separate models were trained for
each DDI type (using ONE-vs-ALL). If none of the separate models is
able to assign a class label to a predicted DDI, a default class label
was chosen (for example, effect). The trained models were applied
only on the extracted DDIs (by the DDI detection module) from the
test dataset. Experiments on the training dataset showed that the
ﬁltering techniques improve both precision and recall with respect
to applying only the hybrid kernel. This team achieved the best
three submitted runs. The only difference between the three runs
was the default class label which was ‘‘int’’, ‘‘effect’’ and ‘‘mecha-
nism’’ for run 1, 2 and 3 respectively. The top run showed an F1
of 0.80 for DDI detection and 0.65 for DDI detection and
classiﬁcation.3.2. Humboldt-Universität zu Berlin team (WBI)
The second best system was developed by the WBI team. The
system relied on two step processes which ﬁrst detected DDIs
using ensembles of ﬁve different classiﬁers, and then the extracted
DDIs were classiﬁed with one of the four proposed types. Several
experiments were conducted combining the following eight
machine learning methods: all-paths graph (APG) [31], the Shallow
Linguistic Kernel (SL), SubTree (ST) kernel [32,33], Spectrum tree
(Spt) [34], Turku Event Extraction System (TEES) [35], the case-
based reasoning Moara system [36] and a self-developed feature
based classiﬁer (SLW), which is an extension of SL. Experiments
were performed using 10-fold cross validation (CV) on the training
set, and showed that the best results were achieved by the
following majority voting ensembles: (1) Moara + SL + TEES, (2)
APG + Moara + SL + SLw + TEES, and (3) SL + SLW + TEES. These
ensembles were submitted as runs. This team was ranked second
behind the FBK-irst team. Its best run was the third one, which
yielded an F1 of 0.76 for DDI detection and 0.609 for DDI detection
and classiﬁcation.
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The third best team was the Uturku team. The TEES system was
used to participate in both tasks: drug named entity recognition
and extraction of DDIs. TEES is a machine learning system based
on SVM, which was originally developed to extract events (and
relations) in the BioNLP shared task. The event extraction is tackled
as a graph generation task where nodes are keywords and edges
are the words that connect nodes. The node detection task is sim-
ilar to named entity recognition, while the edge detection task can
be thought of as a relation extraction task. Deep syntactic features
and information from external domain resources such as DrugBank
or MetaMap [37] were used to model the Turku system. In run 1,
the Uturku system was trained using only a feature set from syn-
tactic parses. In run 2, DrugBank features were added to the syn-
tactic features. Run 3 further extended run 2 with MetaMap
information. The results of each run seem to be very close to each
other. The best performance was provided by run 2 (an F1 of 0.696
for DDI detection and 0.594 for DDI detection and classiﬁcation).
While drug name recognition beneﬁts from the use of domain
knowledge resources, these external resources do not achieve a
signiﬁcant improvement in the relation extraction task. This may
indicate that the extraction of DDIs seems to depend more on
the syntactic interpretation of parse trees. TEES (version 2.1) is
available for research purposes from http://bionlp.utu.ﬁ/eventex-
tractionsoftware.html. The authors also provided their DDI predic-
tions for all DDIExtraction-2013 participants.
3.4. Complutense University of Madrid team (NIL_UCM)
The system was based on SVM using lexical, morphosyntactic
and parse tree features. Information Gain ranker was used to elim-
inate the less informative features. The team submitted two differ-
ent runs: (1) to train a SVM classiﬁer with 5 categories (effect,
mechanism, int, advice, null) and (2) to train a binary SVM classifer
(DDI, non-DDI), and then, the extracted DDI were used to train a
second SVM classiﬁer with four categories (effect, mechanism,
int, advice). The second run achieved better results (an F1 of
0.656 for DDI detection and 0.548 for DDI detection and classiﬁca-
tion) than the ﬁrst one.
3.5. Carlos III University of Madrid team (UC3M)
Thesystemwasbasedon theSLKernel. First, the SLwas trained to
distinguishpositive instances fromnegative instances, and then, a SL
model was trained for each DDI type. The SL kernel uses the follow-
ing features: tokens, lemmas,PoS tagsandentity types. In addition to
the features listed above, the Anatomical Therapeutic Chemical
(ATC) code of each drug name was obtained from the ATC system,3
the drug classiﬁcation system adopted by theWorld Health Organiza-
tion (WHO). The team submitted two runs. In the ﬁrst run, the team
used the default setting of SL, while in the second one, the lemma fea-
turewas replacedby theATCcodeof thedrug. Theﬁrst runachievedan
F1 of 0.676 for DDI detection and 0.537 for DDI detection and classiﬁ-
cation.However, theuseofATCcodes seems togive rise to a signiﬁcant
detriment to the performance with an F1 of 0.537 for DDI detection
and only 0.294 for DDI detection and classiﬁcation.
3.6. University of Wisconsin–Milwaukee and University of Pittsburgh
team (UWM-TRIADS)
The system relied on two step processes: the ﬁrst one detected
DDIs using a binary weighted SVM classiﬁer to discriminate3 www.whocc.no/atc/,positive instances (that is, DDIs) from negative instances, and then,
a multi-class weighted SVM classiﬁer was applied on the extracted
DDIs (by the binary SVM) in order to classify each DDI. The team’s
hypothesis is that separating the detection and classiﬁcation tasks
into two different phases can help to handle the highly unbalanced
class distribution. Texts were transformed into lower-case, drug
names blinded and number were normalized. A feature set of lex-
ical (such as bag of words and bigrams) and semantic features
(synsets from WordNet [38]) was used to train a binary weighted
classiﬁer to discriminate positive instances from negative
instances. Tokens were stemmed and lemmatized. The authors also
used different stopwords lists of different size. The number of false
positives was relatively high since the positive class was favored in
the weighted SVM. The authors also deﬁned a set of post-process-
ing rules which were applied after the binary SVM classiﬁer. For
example, a rule consisted of discarding those pairs of interacting
drugs referring to the same entity. Another example of a rule
was when an interacting drug is a drug class of the other one; in
this case, this pair should be ruled out since, in general, these pairs
represent a hyponym/hyperonym relationship and not an interac-
tion [39]. Other rules were aimed at detecting (without using any
syntactic information) those pairs of drugs appearing in the same
coordinative structure, since in general they are not interacting
drugs.
Then, a multi-class SVM was trained on the set of extracted DDI
classiﬁed by the previous binary classiﬁer. In this case, the team
proposed a rule that would assign the same type to all pairs
obtained from drug mentions in a coordinative structure and other
drug mention.
The team submitted three runs. The only difference between
them was the size of the stopwords list used in each run. Experi-
ments showed that the list of bigest size (263 stopwords) and
the use of stems instead of lemmas achieve better results
(F1 = 0.599 for DDI detection and F1 = 0.47 for DDI detection and
classiﬁcation) than the other settings.
3.7. Fraunhofer SCAI team (SCAI)
This system was based on the combination of three machine
learning techniques: LibLINEAR [40] (linear SVM), Naïve Bayes
and Voting Perceptron. While the ﬁrst run was generated using
only LibLINEAR, the second and third ones were based on majority
and union ensemble learning strategies, respectively. All ML tech-
niques used a rich feature vector consisting of lexical, syntactic and
semantic features. The classiﬁcation of extracted DDIs was per-
formed by a post-processing step. This post-processing step uses
a list of trigger words related for each type DDI which were man-
ually created based on the observation of the MedLine dataset. The
authors also applied an undersampling technique to balance
the corpora and study its inﬂuence on the performance (only on
the training dataset).
According to the ofﬁcial scores, their best result was obtained
by run 3 (union voting strategy) with an F1 of 0.704 for DDI detec-
tion and 0.458 for DDI detection and classiﬁcation. As regards the
results for DDI classiﬁcation, the system achieved the top score
on MedLine (micro F1 = 0.42), however the system ranked at 5th
position for DrugBank. This may be due to the trigger words col-
lected were based on the observation of MedLine abstracts. There-
fore, it would be advisable to deﬁne trigger words for each DDI
type depending on the corpus.
3.8. University of Colorado team (UColorado_SOM)
This team used LIBSVM [41] trained with morphosyntactic,
lexical and semantic features. The team applied the one-vs-all
multi-class classiﬁcation technique to handle the different DDI
Table 5
Machine learning techniques and tools used by the participating teams.
Team ML technique ML tool
FBK-irst Feature-based kernel
Path-enclosed Tree (PET)
kernel
SVM-Light-TK
toolkit
Shallow Linguistic Kernel jSRE
WBI-DDI All-paths graph (APG)
Shallow Linguistic Kernel jSRE
TEES system
SLW method Breeze Library
UTurku SVM SVMmulticlass
NIL_UCM SVM SMO Weka
UC3M Shallow Linguistic Kernel jSRE
SCAI SVM LibLINEAR
UColorado_SOM SVM LibSVM
UWM_TRIADS SVM LibSVM
Table 6
NLP tools and other resources used by the participating teams.
Team NLP tools Knowledge resources
FBK-irst Charniak–Johnson reranking
parser
McClosky’s biomodel
Standford parser
BioEnEx (NER tool for diseases)
[45]
WBI-DDI Charniak–Johnson reranking
parser
McClosky’s biomodel
Standford converter DrugBank
BioLemmatizer [46] Phare Ontology [47]
UTurku Charniak–Johnson reranking
parser
McClosky’s biomodel WordNet
Standford parser tools DrugBank
MetaMap
NIL_UCM TreeTagger [48]
PaiceHusk Stemmer [49]
Standford parser tools
MetaMap
UC3M GATE Standford Parser plug-in ATC system
SCAI Porter Stemming algorithm [50]
Charniak–Lease parser [51]
UColorado_SOM Genia Dependency Parser [52] OpenDMAP [53]
Porter Stemmer WordNet
UWM_TRIADS Standford NLP tools FDA Drug
classiﬁcationa
Dragon tool [54] (a lemmatizer)
a http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/
ucm162549.htm.
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ﬁers. In run 2, the team also added features from TEES analysis pro-
vided by the UTurku team, and in run 3, features used in run 2
along with a list of interaction words were used as feature set.
Their best run was the third one, achieving an F1 of 0.491 for
DDI detection and 0.336 for DDI detection and classiﬁcation.
3.9. Discussion
A common characteristic of all participating systems was the
use of SVMs. While most systems used feature-based methods,
only three teams (FBK-irst, WBI-DDI, UC3M) applied kernel-based
methods which in general achieved better performance than the
feature-based ones. Unlike feature-based methods, kernel-based
methods do not require the explicit deﬁnition of feature vectors.
A kernel-based method contains a kernel function and a kernel
learner. A kernel function is a function that computes the similarity
between two instances (for example, drug pairs). A kernel learner
(such as SVM) is a learning algorithm which performs a learning
task in a feature space. Table 5 gives a detailed view of all the
ML techniques and tools used by the participating systems.
Most participating systems separate the learning problem into
two stages: ﬁrst the DDIs are detected and then they are classiﬁed
into one of the types proposed in the guidelines. The only
exceptions were the UTurku and NIL_UCM team. The TEES system,
developed by the UTurku team, uses a multiclass SVM on a rich
graph-based feature set. The NIL_UC3M team trained a multi-class
SVM classiﬁer with 5 classes (mechanism, effect, advice, int and
null for negative instances). The NIL_UC3M also developed an
approach in which the DDI detection and classiﬁcation stages were
separated. The evaluation on test dataset showed that the two-
stage approach yielded better results than those achieved by the
multi-class classiﬁer.
As regards the two-stage approaches, the ﬁrst stage, the detec-
tion of DDIs, is always performed by a binary classiﬁer responsible
for distinguishing between negative and positive DDIs instances.
Most teams treated each DDI type as a single classiﬁcation sub-
problem (one-vs-all). The SCAI team was the only one that did
not use any machine learning techniques in the classiﬁcation task.
DDI instances detected in the previous step were classiﬁed accord-
ing to a set of trigger words related with each type of DDIs.
As regards the natural language processing (NLP) tools often
integrated into the participating systems, stemming, POS tagging
and syntactic parsing were the most common ones. Stanford parser
tools [42] were widely used by most systems. Around half of the
participating systems used the Charniak–Johnson parser [43] with
David McClosky’s biomodel [44] trained on the GENIA corpus and
unlabeled PubMed articles. From the results of the FBK-irst, WBIand UTurku teams, we can conclude that the parsers for the bio-
medical domain provided better performance than parsers trained
for a general domain.
Some systems also used additional elements, such as lemmati-
zation (WBI and UWM_TRIADS teams), semantic parsing provided
by MetaMap (UTurku and NIL_UCM teams) or disease named
entity recognition (team FBK-irst). Negation detection was only
used by one team (FBK-irst). Surprisingly, only half of the partici-
pating systems used external lexical resources such as dictionaries
or ontologies. Table 6 shows the NLP components and external
resources used by the participating systems.
None of the participating systems made use of any additional
training data collections to develop their systems, which implies
that all systems relied only on the training dataset provided by
the task organizers.
4. Evaluation results
This section summarizes the evaluation results and provides
detailed analysis and discussion.
For the evaluation, the test dataset with gold annotation only
for pharmacological substances was released to participants. Then,
the evaluation was conducted by comparing the annotation pre-
dicted by each system to the gold annotation. The evaluation
results are reported using the standard recall/precision/f-score
metrics.
Table 7 shows the results of the DDI detection task. These
results are not directly comparable with those reported in DDIEx-
traction 2011 due to the use of different training and test datasets
in each edition. However, it should be noted that there has been a
signiﬁcant improvement in the detection of DDIs: almost all
Table 7
Results for DDI detection task on test dataset.
Team Run DrugBank MedLine Overall
Rank P R F1 Rank P R F1 Rank P R F1
FBK-irst 1 1 0.816 0.838 0.827 1 0.558 0.505 0.53 1 0.794 0.806 0.8
2 2 0.816 0.838 0.827 2 0.558 0.505 0.53 2 0.794 0.806 0.8
3 3 0.816 0.838 0.827 3 0.558 0.505 0.53 3 0.794 0.806 0.8
WBI-DDI 1 6 0.857 0.686 0.762 8 0.63 0.358 0.456 6 0.841 0.654 0.736
2 5 0.874 0.696 0.775 12 0.651 0.295 0.406 5 0.861 0.657 0.745
3 4 0.814 0.755 0.783 4 0.625 0.421 0.503 4 0.801 0.722 0.759
UTurku 1 10 0.846 0.614 0.712 20 0.724 0.221 0.339 11 0.841 0.576 0.684
2 9 0.861 0.624 0.724 19 0.778 0.221 0.344 8 0.858 0.585 0.696
3 8 0.843 0.638 0.726 15 0.658 0.263 0.376 9 0.833 0.602 0.699
SCAI 1 11 0.836 0.619 0.711 7 0.688 0.347 0.462 10 0.826 0.592 0.69
2 12 0.837 0.617 0.71 17 0.686 0.253 0.369 12 0.829 0.581 0.683
3 7 0.796 0.681 0.734 6 0.431 0.526 0.474 7 0.748 0.666 0.704
UC3M 1 13 0.656 0.758 0.703 13 0.392 0.421 0.406 13 0.632 0.725 0.676
2 19 0.415 0.814 0.549 10 0.313 0.642 0.421 19 0.404 0.798 0.537
NIL_UCM 1 16 0.615 0.615 0.615 22 0.419 0.137 0.206 16 0.608 0.569 0.588
2 14 0.673 0.688 0.68 21 0.548 0.242 0.336 14 0.667 0.645 0.656
UWM_TRIADS 1 17 0.525 0.689 0.596 11 0.415 0.424 0.419 17 0.517 0.664 0.581
2 15 0.573 0.665 0.616 9 0.427 0.446 0.436 15 0.561 0.644 0.599
3 18 0.465 0.746 0.573 5 0.387 0.63 0.479 18 0.458 0.735 0.564
UColorado_SOM 1 22 0.387 0.739 0.508 16 0.256 0.663 0.37 21 0.37 0.731 0.492
2 20 0.391 0.765 0.518 14 0.28 0.663 0.394 22 0.378 0.755 0.504
3 21 0.422 0.646 0.511 18 0.253 0.6 0.356 23 0.398 0.641 0.491
Table 8
Results for DDI detection and classiﬁcation task on test dataset.
Team Run DrugBank MedLine Overall
Rank P R F1 Rank P R F1 Rank P R F1
FBK-irst 1 3 0.654 0.672 0.663 4 0.407 0.368 0.387 3 0.633 0.642 0.638
2 1 0.667 0.686 0.676 2 0.419 0.379 0.398 1 0.646 0.656 0.651
3 2 0.664 0.682 0.673 3 0.419 0.379 0.398 2 0.643 0.653 0.648
WBI-DDI 1 6 0.702 0.561 0.624 7 0.463 0.263 0.336 6 0.685 0.532 0.599
2 5 0.707 0.563 0.627 12 0.488 0.221 0.304 5 0.695 0.53 0.601
3 4 0.657 0.609 0.632 5 0.453 0.305 0.365 4 0.642 0.579 0.609
UTurku 1 9 0.723 0.525 0.608 18 0.517 0.158 0.242 9 0.714 0.489 0.581
2 7 0.738 0.535 0.62 16 0.593 0.168 0.262 7 0.732 0.499 0.594
3 8 0.706 0.534 0.608 13 0.5 0.2 0.286 8 0.694 0.502 0.582
NIL_UCM 1 12 0.54 0.541 0.54 22 0.387 0.126 0.19 12 0.535 0.501 0.517
2 10 0.566 0.579 0.573 19 0.357 0.158 0.219 10 0.557 0.538 0.548
UC3M 1 11 0.518 0.598 0.555 15 0.265 0.284 0.274 11 0.495 0.568 0.529
2 21 0.231 0.454 0.306 21 0.138 0.284 0.186 21 0.222 0.437 0.294
SCAI 1 15 0.546 0.404 0.464 1 0.625 0.316 0.42 14 0.551 0.395 0.46
2 16 0.545 0.402 0.463 8 0.6 0.221 0.323 16 0.548 0.384 0.452
3 14 0.513 0.439 0.473 6 0.31 0.379 0.341 15 0.486 0.433 0.458
UWM_TRIADS 1 17 0.407 0.534 0.462 10 0.309 0.315 0.312 17 0.4 0.513 0.449
2 13 0.452 0.524 0.485 9 0.312 0.326 0.319 13 0.439 0.505 0.47
3 18 0.361 0.579 0.445 11 0.247 0.402 0.306 18 0.35 0.562 0.432
UColorado_SOM 1 22 0.166 0.317 0.218 20 0.13 0.337 0.188 22 0.161 0.319 0.214
2 20 0.258 0.503 0.341 14 0.196 0.463 0.275 20 0.25 0.499 0.334
3 19 0.288 0.441 0.349 17 0.173 0.411 0.244 19 0.272 0.438 0.336
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sure above 65.4% (the best F1 in DDIExtraction 2011). The increase
in the size of the corpus made for DDIExtraction 2013, the inclu-
sion of different types of documents and the quality of their anno-
tations may have contributed signiﬁcantly to this improvement.
The best system (run 1 submitted by the FBK-irst team) had preci-
sion of 83.8% and recall of 83.8% (F1 82.7%) on DrugBank dataset,
compared to its precision of 55.8% and 55.5% recall (F1 53%) on
the MedLine dataset. It should be noted that there is almost a 30point F-measure difference between the DrugBank dataset and
the MedLine dataset. Indeed a common characteristic observed in
all systems was the strong decrease in their results on the MedLine
dataset compared to the DrugBank dataset. This may be justiﬁed
by the different styles of the two sources. In the one hand, the texts
taken from DrugBank are manually curated to provide brief
descriptions of DDIs. Therefore, DrugBank contains short and con-
cise sentences. On the other hand, the main topic of the scientiﬁc
texts from MedLine would not necessarily be on DDIs. Moreover,
Fig. 2. Micro-Avg F1 scores by DDI type on the DrugBank test dataset.
Fig. 3. Micro-Avg F1 scores by DDI type on the MedLine test dataset.
Table 9
Analysis of false negatives in the DrugBank dataset.
Error cause FBK-
irst
WBI UTurku Examples
Detection of coordinate structures
required
14 23 17 E1, E2
Detection of appositions required 28 18 96 E3, E4
Unusual patterns for coadministration 11 18 27 E5, E6
Unusual patterns for DDI 28 51 20 E7, E8
Long DDI descriptions 6 27 20 E9
Unobvious DDIs 10 6 27 E11, E12
Resolution of percentages, dosages and
temporal expressions required
8 4 26 E13, E14
Resolution of anaphora required 7 17 17 E15
Resolution of cataphora required 27 40 46 E16
Resolution of complex and compound
sentences required
6 13 36 E17
Total 143 217 332
Table 10
Example of false negatives in the DrugBank dataset.
ID Example DDIs not detected
E1 Several studies demonstrate a decrease in the
bioavailability of methyldopae1 when it is
ingested with ferrous sulfatee2 or
ferrous gluconatee3
ðe1; e3Þ
E2 Sulfoxonee1 may increase the effects of
barbituratese2 , tolbutamidee2 , and
uricosuricse4
ðe1; e2Þ; ðe1; e4Þ
E3 Concurrent administration of
bacteriostatic antibioticse1 (e.g.,
erythromycine2 , tetracyclinee3 ) may diminish
the bactericidal effects of penicillinse4 by
slowing the rate of bacterial growth
ðe3; e4Þ
E4 Other inhibitors of the cytochrome P450 3A4
enzyme system, such as antimycotic agentse1
(e.g., itraconazolee2 and miconazolee3 ) or
macrolide antibioticse4 (e.g., erythromycine5
and clarithromycine6 ), may alter oxybutynine7
mean pharmacokinetic parameters (i.e., Cmax
and AUC)
ðe1; e7Þ; ðe2; e7Þ; ðe3; e7Þ;
ðe4; e7Þ; ðe5; e7Þ; ðe6; e7Þ
E5 The occurrence of stupor, muscular rigidity,
severe agitation, and elevated temperature has
been reported in some patients receiving the
combination of selegilinee1 and meperidinee2
ðe1; e2Þ
E6 The addition of aspirine1 to Streptokinasee2 in
the risk of minor bleeding
ðe1; e2Þ
Table 11
Example of false negatives in the DrugBank dataset (cont. 2).
ID Example DDIs not
detected
E7 There is usually complete cross-resistance between
PURINETHOLe1 and TABLOIDe2
ðe1; e2Þ
E8 Concomitant treatment with NEXAVARe1 resulted in
a 21% increase in the AUC of doxorubicine2
ðe1; e2Þ
E9 Other drugs such as cisapridee1 or pimozidee2 , which
are metabolised by hepatic CYP3A isozymes have
been associated with QT interval prolongation and/or
cardiac arrhythmias (typically torsades de pointe) as a
result of increase in their serum level subsequent to
interaction with signiﬁcant inhibitors of the isozyme,
including some macrolide antibacterialse3
ðe1; e3Þ; ðe2; e3Þ
E10 Certainmacrolidese1 interact with terfenadinee2 and
astemizolee3 leading to increased serum
concentrations of the latter
ðe1; e2Þ; ðe1; e3Þ
E11 Furosemidee1 and probably other loopdiureticse2
given concomitantly with metolazonee3 can cause
unusually large or prolonged losses of ﬂuid and
electrolytes
ðe2; e3Þ
E12 Concomitant administration of alcohole1 had a
minimal effect on plasma levels of mirtazapinee2
ðe1; e2Þ
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common the use of long and subordinated sentences. The error
analysis (see Section 5) showed that the systems fall drastically
for long and complex sentences. Another possible reason may be
the different size between the two corpora. In addition, while the
best system obtained balanced results in both precision and recall,
the rest of the participants showed biased scores towards one or
other metric.
As stated earlier, the use of biomedical parsers seems to provide
better performance than parsers trained for a general domain, and
the kernel-based systems in general overcame the feature-based
ones.The DDI classiﬁcation task does not only consist of the identiﬁ-
cation of all possible pairs of interacting drugs, but also their clas-
siﬁcation. The results did not exceed an F1 of 65.1% (FBK-irst team)
on the DrugBank dataset and 42% (SCAI team) on the MedLine
dataset (see Table 8). These results clearly demonstrate that the
identiﬁcation of what type of information (such as an advice, an
effect or information about the way the interaction occurs) is being
used to describe a DDI may be a very complex task. As in the DDI
detection task, all systems (except the runs submitted by the FBK-
irst team) showed a marked disparity between precision and recall.
Figs. 2 and 3 show the results for each type of DDI on the Drug-
Bank and MedLine test datasets, respectively. From each partici-
pant, we only select its best run. Fig. 2 suggests that some types
Table 12
Example of false negatives in the DrugBank dataset (cont. 3).
ID Example DDIs not
detected
E13 Concomitant administration of aspirine1 (1000 mg
TID) to healthy volunteers tended to increase the AUC
(10%) and Cmax (24%) of meloxicame2
ðe1; e2Þ
E14 All patients taking NSAIDse1 should interrupt dosing
for at least 5 days before, the day of, and 2 days
following ALIMTAe2 administration
ðe1; e2Þ
E15 Althoughminoxidile1 does not itself cause orthostatic
hypotension, its administration to patients already
receiving guanethidinee2 can result in profound
orthostatic effects
ðe1; e2Þ
E16 Drugs which may potentiate the myeloproliferative
effects of Leukinee1 , such as minoxidile2 lithium and
corticosteroidse3 , should be used with caution
ðe1; e2Þ; ðe1; e3Þ
E17 Mexitile1 does not alter serum digoxine2 levels but
magnesium—aluminum hydroxidee3 , when used to
treat gastrointestinal symptoms due to Mexitile4 , has
been reported to lower serum digoxine5 levels
ðe3; e5Þ
Table 13
Analysis of false negatives in the MedLine dataset.
Error cause FBK-
irst
WBI UTurku Examples
Detection of coordinate structures
required
3 0 7 E18
Detection of appositions required 5 6 3
Unusual patterns for coadministration 17 17 15 E20
Unusual patterns for DDI 5 10 30 E21
Long DDI descriptions 3 4 2 E22
Unobvious DDIs 3 3 2 E23
Resolution of percentages, dosages and
temporal expressions required
4 7 9 E24
Resolution of anaphora required 2 2 2 E25
Resolution of cataphora required 0 0 2 E26
Resolution of complex and compound
sentences required
5 6 2 E27
Total 47 55 74
Table 14
Example of false negatives in the MedLine dataset.
ID Example DDIs not detected
E18 AAV2e1 -mediated retinal
transduction is improved by
co-injection of
heparinase IIIe2 or
chondroitin ABC lyasee3
ðe1; e3Þ
E19 It is better to avoid prescribing
isoenzyme CYP 2D6 inhibitors
to women treated with
tamoxifene1 for breast cancer,
especially
SSRI antidepressantse2 such
as paroxetinee3 and
fluoxetinee3
ðe1; e3Þ; ðe1; e2Þ; ðe1; e3Þ
E20 Warfarine1 users who
initiated citaloprame2 ,
fluoxetinee3 , paroxetinee4 ,
amitriptylinee5 , or
mirtazapinee6 had an
increased risk of
hospitalization for
gastrointestinal bleeding
ðe1; e2Þ; ðe1; e3Þ; ðe1; e4Þ; ðe1; e5Þ; ðe1; e6Þ
E21 Reduction of PTH by
cinacalcete1 is associated with
a decrease in darbepoetine2
requirement
ðe1; e2Þ
E22 In an in vitro assay,
lapatinibe1 induced HER2
expression at the cell surface
of HER2-positive breast cancer
cell lines, leading to the
enhancement of Herceptine2 -
mediated ADCC
ðe1; e2Þ
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dataset, being the advice relationship being the easiest one. One
possible explanation for this could be that recommendations or
advice regarding a drug interaction are typically described by very
similar text patterns such as ‘DRUG should not be used in combina-
tion with DRUG’ or ‘Caution should be observed when DRUG is admin-
istered with DRUG’. The participating systems achieve very similar
performance for the mechanism and effect relationships, while
the int relationships seem to be the most difﬁcult to extract. This
may be because the proportion of instances of int relationship
(5.6%) in the DDI corpus is much smaller than those of the rest of
the relations (41.1% for effect, 32.3% for mechanism and 20.9% for
advice).
5. Error analysis
The aim of this section is to perform a detailed error analysis
with the objective of providing a road map for future work in the
extraction of DDIs from texts. To this end, we focus on the study
of the main source of errors produced by the systems developed
by the following teams: FBK-irst, WBI-DDI and Uturku. For each
team, we only analyzed their best runs. The reason for this choice
is that these systems were the top-performing in DDIExtraction
2013.5.1. Analysis of false negatives
Tables 9 and 13 present the main causes for the false negatives
in the DrugBank dataset and the MedLine dataset, respectively.
From Table 9, we can see that one of the most important factors
contributing to false-negatives in DrugBank texts is the lack of
cataphora resolution in the three systems. The resolution of the
appositions in sentences, prior to the detection of DDIs, could allow
to further improve the performance, particularly the FBK-irst and
UTurku systems. Similarly, the resolution of anaphora and the
detection of coordinate structures may also help to reduce false
negatives, though fewer than the resolution of cataphoras and
appositions. Another major cause of false negative is that many
DDIs are described with very unusual text patterns. The high var-
iability of natural language expression allows DDIs to be able to
be composed using many different lexical and syntactic realiza-
tions. Classiﬁers have problems in detecting these cases since they
are probably unrepresented in the training data. Tables 10–12
show some examples of false negatives in the DrugBank dataset.
Long, complex and compound sentences are other sources of
false negatives. Many DDIs are described in long and complex sen-
tences, which usually have a complex syntactic and lexical struc-
ture. Sentences with several embedded subordinated clauses are
often encountered both in DrugBank and MedLine. Moreover, these
sentences also pose a challenge to syntactic parsers due to their
high levels of ambiguity. This may be one of the reasons why the
methods using syntactic features from parsers (e.g. Standford par-
ser) are not capable of dealing with these types of sentence. The
FBK-irst system shows a lower rate of false negatives (only 2%
are classiﬁed as long DDI descriptions and only 4% as complex
and compound sentences) compared to the other two systems. In
this case, the use of semantic roles, which were used to rule out
Table 15
Example of false negatives in the MedLine dataset (cont. 2).
ID Example DDIs not
detected
E23 However, the evidence for a calciume1 effect on
irone2 absorption mainly comes from studies that did
not isolate the effect of calcium from that of other
dietary components, because it was detected in
single-meal studies
ðe1; e2Þ
E24 Systemic and apparent oral midazolame1 clearance
were 24% (269 73 vs. 354 102 ml/min, P = 0.022) and
31%, respectively, lower in cyclosporinee2 -treated
patients (n = 20) than in matched tacrolimus-treated
patients (n = 20)
ðe1; e2Þ
E25 Acute administration of hemantanee1 or
doxycyclinee2 failed to inﬂuence locomotion in mice,
while their combination normalized motor activity
ðe1; e2Þ
E26 Regulatory agencies state that the combination of
clopidogrele1 and the CYP2C19 inhibitors
omeprazolee2 and esomeprazolee3 should be avoided
ðe1; e2Þ; ðe1; e3Þ
E27 Exposure to oral S-ketaminee1 is unaffected by
itraconazolee2 but greatly increased by ticlopidinee3
ðe1; e3Þ
Table 16
Analysis of false positives in the DrugBank dataset.
Error cause FBK-
irst
WBI UTurku Examples
Incorrect pair 57 60 36 E28
Annotation error 27 19 19 E29
Resolution of coordinated structures
required
31 21 12 E30
Same drug 8 28 10 E31
Lack of evidence 41 21 9 E32
Resolution of apposition structures
required
3 3 3
Total 167 152 89
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syntactic analysis.
Some sentences describe DDIs without giving an absolute cer-
tainty of their existence or using uncommon patterns. For example,
in the sentence ‘Lapatinib may have the potential to convert Hercep-
tin-refractory to Herceptin-sensitive tumors in HER2-positive breast
cancer by up-regulation of the cell surface expression of HER2’, it is
even difﬁcult for a human being to determine whether they are
DDIs or not. The detection of dosages, numeric and temporal
expressions can also help to improve the performance of the sys-
tems, since many sentences describe DDIs including additional
information such as dosages, dosage regimen or percents of change
of parameters, among others.Table 17
Example of false positives in the DrugBank dataset.
ID Example
E28 Although ibuprofene1 (400 mg qid) can be administered with ALIMTAe2 in pati
function (creatinine clearance 80 mL/min), caution should be used when admi
concurrently with ALIMTAe4 to patients with mild to moderate renal insufﬁcie
clearance from 45 to 79 mL/min)
E29 Careful monitoring of phenytoine1 concentrations in patients receiving DIFLUC
recommended
E30 It may also interact with thiazidese1 (increased thrombocytopenia), cyclospor
nephrotoxicity), sulfonylurea agentse3 (increased hypoglycemic response), wa
anticoagulant effect), methotrexatee5 (decreased renal excretion of methotrex
(decreased hepatic clearance of phenytoine8 )As regards the MedLine dataset (see Table 13), false negatives
have similar error sources to those in the DrugBank dataset. The
major cause of false negatives for all three systems is their inability
to detect those DDIs described by patterns that are very scarce,
even unrepresented, in the training data. This may be due mainly
to the small size of the training dataset from MedLine. The detec-
tion of doses, numerical and temporal expressions also seem to
be another signiﬁcant problem which these systems have to face
in order to improve their performance in the detection of DDIs.
Anaphoras, cataphoras, coordinated structures and appositions
have a much less signiﬁcant effect on the false negatives in the
MedLine dataset than in the DrugBank dataset. A possible reason
for this could be that many texts in DrugBank provide descriptions
of DDIs involving a drug and a list of drugs. The use of these lin-
guistic structures is very common and useful in providing these
kinds of description. Tables 14 and 15 show some examples of false
negatives in the MedLine dataset.
5.2. Analysis of false positives
Tables 16 and 19 show the main causes of false positives in
DrugBank and MedLine, respectively.
The major cause of false positives in DrugBank refers to sen-
tences in which interacting drugs have more than one mention.
The systems were able to detect that there was an interaction
between two drugs, but failed to identify their mentions that were
actually involved in this DDI. The ﬁrst example in Table 18 (see
E28) shows a sentence describing a DDI between ibuprofen and ALI-
MTA. We can see that both drugs appear twice in the sentence, but
only their last two mentions are involved in the description of a
DDI. However, the three systems failed to detect this DDI, because
they proposed the pair formed by the ﬁrst two mentions of the
drugs. Annotation errors (see E29 in Table 17) are the second
source of false positives in DrugBank. The candidate pairs were cor-
rectly detected by the systems, but were not annotated in the DDI
corpus. Another cause of false positives was the systems’ incapabil-
ity to distinguish between drugs constituting a coordinate struc-
ture, and therefore, to recognize that they are not describing a
DDI (see E30 in Table 17). Notably, one of the main sources of false
positives would be ﬁne with a simple rule that prevented mentions
of drugs referring to the same drug which could be considered as a
candidate DDI (see E31 in Table 18). The lack of evidence to con-
ﬁrm the existence of a DDI was another source of false positives
(see E32 in Table 18). In fact, it was the main cause of false posi-
tives in MedLine (see Table 19 and Table 20).6. Statistical analysis of signiﬁcance
McNemar’s signiﬁcance test [55] is a v2-based signiﬁcance test
used to compare two groups, such as two classiﬁers or twoFP Gold
DDIs
ents with normal renal
nistering ibuprofene3
ncy (creatinine
ðe1; e2Þ ðe3; e4Þ
ANe2 and phenytoin is ðe1; e2Þ
inee2 (increased
rfarine4 (increased
atee6 ), phenytoine7
ðe1; e7Þ; ðe2; e7Þ; ðe3; e7Þ; ðe4; e7Þ; ðe5; e7Þ; ðe6; e7Þ
Table 18
Example of false positives in the DrugBank dataset (cont. 2).
ID Example FP Gold DDIs
E31 Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressantse1 and ELDEPRYLe2 and
selective serotonin reuptake inhibitorse3 and ELDEPRYLe4
ðe2; e4Þ ðe1; e2Þ; ðe3; e4Þ
E32 There are no clinical data on the use of MIVACRONe1 with other nondepolarizing neuromuscular blockingagentse2 ðe1; e2Þ
E33 Tetracyclinee1 , a bacteriostatic antibiotice2 , may antagonize the bactericidal effect of penicilline3 and concurrent use of these drugs
should be avoided
ðe2; e3Þ ðe1; e3Þ
Table 19
Analysis of false positives in the MedLine dataset.
Error cause FBK-irst WBI UTurku Examples
Incorrect pair 11 10 2 E34
Annotation Error 2 1 1 E35
Lack of evidence 35 13 3 E36
Total 48 24 6
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compare the performance of the different runs and determine
whether or not they differ signiﬁcantly. Thus, for each pair of runs
Ra and Rb, their corresponding models were performed on the test
dataset, and the contingency matrix was then built for any pair of
runs. The classiﬁcation of each example in the test dataset by each
model was recorded, counting the number of examples correctly
classiﬁed by Ra and Rb (n11), the number of examples correctly clas-
siﬁed by Ra but not by Rb (n10), the number of examples misclassi-
ﬁed by Ra but not by Ra (n01), and the number of examples
misclassiﬁed by both Ra and Rb (n00).
McNemar’s test is based on a v2 goodness-of-ﬁt test comparing
the distribution of counts expected under the null hypothesis to
the counts observed. The null hypothesis H0 states that the two
classiﬁers (runs) should have the same error rate (i.e., n10 ¼ n01).
According to Dietterich [56], under the null hypothesis the follow-
ing statistic (see Eq. (1)) is distributed as an v2 distribution with
one degree of freedom.
v ¼ ðjn01  n10j  1Þ
2
n01 þ n10 ð1Þ
To test for signiﬁcance, v2 was compared to the appropriate v2
table. Results with a probability greater than or equal to 0.05 are
generally considered to be signiﬁcant. Thus, the null hypothesis
was correct if v2 was lower than v21;0:05 ¼ 3:841459. In other cases,
the null hypothesis could be rejected in favor of the hypothesis
that the two runs produce different levels of performance.
First, we analyzed whether the runs submitted by a same team
were statistically signiﬁcant from each other. The runs submitted
by the top four teams (FBK-irst, WBI, UTurku and SCAI) did not
show statistically signiﬁcant differences between the other runs
of the same team. However, when comparing the two runs submit-
ted by the NIL_UCM, a statistically signiﬁcant difference did exist
between their results. The ﬁrst run used a multiclassiﬁer with 5
categories (effect, mechanism, int, advice, null), while its second
run followed a two-stage approach in which DDIs were initiallyTable 20
Example of false positives in the MedLine dataset.
ID Example
E34 Moxifloxacine0 and Lomefloxacine1 reacts faster with sucralfatee2 and gelusil
erythromycine4 in basic media and multi-minerals in neutral media
E35 Improved parathyroid hormone control by cinacalcete0 is associated with reduc
patients with end-stage renal disease
E36 On day 8, a single panobinostate0 dose was co-administered with ketoconazodetected using a binary classiﬁcation, and then these detected DDIs
were used to train a second SVM classiﬁer with four categories
(effect, mechanism, int, advice). Similarly, we also observed a
strong statistically signiﬁcant difference between the two runs
submitted by the UC3M team. The second run used the ATC code
instead of the lemma feature in the shallow linguistic kernel. This
is the only difference between the two runs and it seems to give
rise to a strong decrease in the performance. The only differences
between the runs submitted by the UWM_TRIADS team were the
size of the stopwords lists used in each run and the use of stems
instead of lemmas. These changes led to statistically signiﬁcant dif-
ferences between the results of the three runs. As regards the runs
submitted by the UColorado_SOM team, the use of a list of inter-
acting words as an additional feature in the third run yielded the
best results and also brought about statistically signiﬁcant differ-
ences with the other two runs.
To study whether the runs submitted by the teams obtained
statistically signiﬁcant results with respect to the other participat-
ing teams, we only chose the best run from each team. Table 21
summarizes the v statistic values for the pairwise comparison of
the eight runs using the McNemar signiﬁcance test (i.e., a total of
28 comparisons). Each cell of this pairwise comparison matrix rep-
resents the v statistic value for a given pair of runs. Table 21 shows
that in general most systems signiﬁcantly differ from all others.
The UTurku system does not signiﬁcantly differ from the SCAI sys-
tem. Similarly, the differences in performance between the UC3M
system and the NIL-UCM system are not signiﬁcant.7. Ensemble
In order to investigate whether it is possible to improve the best
scores obtained in DDIExtraction 2013, we built different ensemble
systems by combining the submitted runs.
We chose to use a majority voting-based ensemble strategy due
to its simple implementation. In this strategy, each system votes
for a particular prediction (DDI or non-DDI), and the class with
the most votes is selected as the ﬁnal decision. In case of a tie,
the ﬁnal prediction was set to DDI, improving the recall (though
at the expense of reducing the precision). This decision is based
on the fact that all the participating systems have achieved better
precision than recall. Therefore, in order to improve the F-measure,
it is necessary to improve the recall. The main shortcoming of
majority voting is that this strategy does not take in account that
sometimes the minority predictions are correct.FP Gold DDIs
e3 in acidic media whereas with ðe2; e3Þ ðe0; e2Þ; ðe0; e3Þ; ðe0; e4Þ,
ðe1; e2Þ; ðe1; e3Þ; ðe1; e4Þ
tion in darbepoetine1 requirement in ðe0; e1Þ
lee0 ðe0; e1Þ
Table 21
v statistic values using McNemar’s test. The equivalent p-values are shown in parenthesis.
WBI-3 UTurku-2 SCAI-1 UC3M-1 NIL_UCM-1 UWM-2 UCOLORADO-3
FBK-2 8.2 (0.00418904) 24.1 (0.00000091) 30.7 (0.00000003) 163.9 (0.0) 112.4 (0.0) 266.6 (0.0) 626.2 (0.0)
WBI-3 – 6.9 (0.00861957) 11.3 (0.00077507) 122.8 (0.0) 77.2 (0.0) 199.6 (0.0) 551.9 (0.0)
UTURKU-2 – – 0.7848⁄ (0.37567714) 47.7 (0.0) 41.6 (0.0) 143.5 (0.0) 496.3 (0.0)
SCAI-1 – – – 36.7 (0.0) 31.2 (0.00000002) 122.7 (0.0) 454.0 (0.0)
UC3M-1 – – – – 0.42⁄ (0.51693704) 28.8 (0.00000008) 270.3 (0.0)
NIL_UCM-1 – – – – – 40.8 (0.0) 293.7 (0.0)
UWM-2 – – – – – – 132.7 (0.0)
* Not statistically signiﬁcant differences.
Table 22
Ensemble systems results. 3bestruns: the three runs of FBK-irst; 6bestruns: the three runs of FBK-irst and the three runs of WBI; 9BestRuns: the three runs of the three top teams:
FBK-irst, WBI and UTurku; 3BestRuns3BestTeams: the best runs of the three best teams: FBK-irst, WBI and UTurku; ExceptUColorado_SOM: best runs of each team, except
UColorado; ExceptUWM_UColorado_SOM: best runs of each team, except UWM and UColorado; ExceptUC3M_UColorado_SOM: best runs of each team, except UColorado and
UC3M; ExceptSCAI_UColorado_SOM: best runs of each team, except UColorado and SCAI; ExceptNIL_UCM__UColorado_SOM: best runs of each team, except UCM-NIL and
UColorado.
Row Team DrugBank MedLine Overall
P R F1 P R F1 P R F1
1 Best system (FBK run 1) 0.816 0.838 0.827 0.558 0.505 0.53 0.794 0.806 0.8
2 All runs 0.8617 0.7681 0.8122 0.6923 0.3789 0.4898 0.8512 0.7303 0.7861
3 3bestruns 0.8161 0.8382 0.827 0.5581 0.5053 0.5304 0.7938 0.8059 0.7998
4 6bestruns 0.8004 0.8575 0.828 0.5618 0.5263 0.5435 0.7799 0.8253 0.802
5 9BestRuns 0.885 0.7489 0.8113 0.6596 0.3263 0.4366 0.8717 0.7079 0.7813
6 Best runs of each team 0.8485 0.7919 0.8192 0.678 0.4211 0.5195 0.8371 0.7559 0.7944
7 Maximizing recall 0.8559 0.7794 0.8159 0.6667 0.3789 0.4832 0.844 0.7406 0.7889
8 3BestRuns3BestTeams 0.8662 0.7613 0.8104 0.6792 0.3789 0.4865 0.8542 0.7242 0.7839
9 ExceptUColorado 0.8714 0.759 0.8114 0.6522 0.3158 0.4255 0.8333 0.7661 0.7983
10 ExceptUWM_UColorado 0.8439 0.8009 0.8218 0.6885 0.4421 0.5385 0.8333 0.7661 0.7983
11 ExceptUC3M_UColorado 0.8843 0.7523 0.813 0.7442 0.3368 0.4638 0.8767 0.712 0.7858
12 ExceptSCAI_UColorado 0.8521 0.7692 0.8086 0.7091 0.4105 0.52 0.8429 0.7344 0.7849
13 ExceptUCM_UColorado 0.8612 0.7579 0.8063 0.6981 0.3895 0.5 0.8508 0.7222 0.7812
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strategy. In this strategy, if a candidate pair is classiﬁed as DDI
by at least one system, then the ﬁnal decision for this pair will
be DDI. A pair will be classiﬁed as negative only when it is classi-
ﬁed as negative by all the systems. This strategy achieves a signif-
icant improvement of the recall (above 90%), but at expense of
a strong decrease in precision (under 55%), and thereby, the
F-measure also suffers a signiﬁcant decrease (no more than 69%).
Therefore, we decided not to use this strategy in our ensemble
system.
As mentioned above, we conducted numerous experiments
using different combinations of the ﬁnal submissions. Table 22
shows the experimental results of some of these ensembles. For
example, the second row shows the results obtained by combining
all the runs. Since the UWM-TRIAD team did not provide any pre-
diction for a total of 202 pairs, we decided to consider their unseen
pairs as non-DDIs. In general, the ensemble systems do not over-
come the FBK-irst system (see row 1 in Table 22). Therefore, we
can conclude that the FBK-irst system is considerably more robust
than the other systems.
We decided to evaluate whether removing the predictions of
some teams had a positive or negative effect on the ﬁnal perfor-
mance. For example, we removed the predictions provided by
the UCOLORADO_SOM team since its performance is markedly
below that of the rest of the teams. However, this did not achieve
an improvement in the results (see row 9 in Table 22 of the ensem-
ble system, particularly on the MedLine dataset).
The ensemble made by the best run of each team (see row 6 in
Table 22) achieves very close results to those reported by the best
system, but not better than them. We also conducted an experi-
ment in which we selected, for each team, the run that maximized
recall (see row 7 in Table 22). This experiment showed lower
results than the previous experiment.Only one ensemble system (see the ‘‘6bestruns’’ row in Table 22)
manages to improve the results of the FBK system very slightly.
This ensemble consists of the 6 best submitted runs, that is, the
runs submitted by the FBk-irst and WBI-DDI teams. This may indi-
cate that if the FBK-irst system is extended to integrate the kernels
proposed by the WBI teams, its performance may be improved.
However, the difference between this ensemble and the FBK-irst
system does not seem to be statistically signiﬁcant.8. Conclusion and future directions
The goal of DDIExtraction is to promote the development of
information extraction techniques applied to the detection of drug
names and DDIs from biomedical texts. There were a total of 38
runs which were submitted by 14 different teams from 7 different
countries (6 of the teams participated in the drug name recognition
task, while 8 participated in the DDI extraction task). The highest
F1 scores obtained was 71.5% for drug name recognition and clas-
siﬁcation and 65.1% for extraction and classiﬁcation of DDIs. This
paper focuses on the extraction of DDIs. We have presented the
main approaches used and examined the main challenges, which
have yet to be resolved.
As regards the task of detection of DDIs, the participating sys-
tems demonstrated substantial progress over the previous DDI
Extraction 2011. The best team, FBK-irst, achieved a competitive
F-measure of 82.7% on DrugBank texts. However, performance on
MedLine was lower mainly due to the limited size of its training
dataset. Another possible reason may be that MedLine texts have
a greater complexity than DrugBank texts. All teams used machine
learning methods, speciﬁcally SVM. In general, non-linear kernel-
based methods overcome linear SVMs.
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The error analysis points out the main limitations of the participat-
ing systems. Current approaches have focused on syntactic aspects,
drawing their attention to the sentence structure. The resolution of
linguistic phenomena such as cataphora, anaphora, appositive and
coordinate structures and complex sentences, among others, could
lead to better performance.
On the other hand, few participating systems took into account
the sentence meaning. Approaches using domain knowledge have
been recently applied with success to the pharmacological domain
[57,58]. The use of knowledge resources can reduce the number of
false positives generated by the current DDI extraction systems
because these resources can help to distinguish between those
pairs of drugs that are DDIs from those that are not. The informa-
tion required for a semantic-based IE system can be taken, for
example, from pharmacological databases such as DrugBank, Phar-
mGKB [59], SIDER [60] or KEGG [61], among others. Some of them
describe speciﬁc pairs of interacting drugs. For example, in Drug-
Bank 39 different drugs that interact with ciproﬂoxacin are
described. On the other hand, a larger number of DDIs can be
deduced indirectly by exploiting, for example, the drug-protein
relationships. Thus, the relationships of two different drugs with
the same protein can be used to infer the mechanism leading to
a DDI [62]. For example, ciproﬂoxacin is described to inhibit the
activity of the metabolic enzyme CYP1A2, and duloxetine is
described to be metabolized by CYP1A2. Therefore, there could be
an interaction between ciproﬂoxacin and duloxetine. Similarly, the
relationships of two different drugs with the same adverse drug
reaction (ADR) can be used to infer possible DDIs [63]. For example,
morphine is related to the side effect central nervous system depres-
sion. Therefore, other drugs related to the same ADR, such as
oxycodone, could interact with morphine.
Up to now, the main limitation for the development of seman-
tic-based approaches has been the availability of appropriate
knowledge bases in a machine-readable format. However, the cre-
ation of these knowledge bases is becoming more feasible and
common in the pharmacological domain [64,65]. This is due to
the increasing number of databases and web servers providing
structured and semi-structured pharmacological information, such
as DrugBank or KEGG. Moreover, there are different community
projects such as BIO2RDF [66] or LODD [67], which work to link
the various sources of biological and pharmacological data
together, enabling the integration of several pharmacological
aspects described in different databases [68]. Another important
factor is the proliferation of biomedical ontologies to store and for-
mally represent domain knowledge. Ontologies enable the integra-
tion of the information disperse through different and
heterogeneous databases and provide artifacts that can be
exploited by IE systems [69].
Therefore, future directions for DDI extraction might entail the
combination of syntactic and semantic information. In addition,
increasing the size of training dataset, in particular for MedLine,
would also have a very positive impact on the results.
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